Addex Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Addex Therapeutics
ADXN Stock  USD 7.67  0.04  0.52%   
Addex Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Addex Therapeutics' valuation are provided below:
Gross Profit
-525.7 K
Market Capitalization
9.5 M
Enterprise Value Revenue
165.7063
Revenue
158.5 K
Earnings Share
(9.24)
We have found one hundred twenty available fundamental signals for Addex Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Addex Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 5th of February 2026, Market Cap is likely to drop to about 6.1 M. In addition to that, Enterprise Value is likely to drop to about 2.5 M

Addex Therapeutics Total Revenue

345,507

Check Addex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Addex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 222.4 K, Interest Expense of 3 K or Total Revenue of 345.5 K, as well as many indicators such as Price To Sales Ratio of 14.95, Dividend Yield of 0.0 or PTB Ratio of 0.5. Addex financial statements analysis is a perfect complement when working with Addex Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Addex Stock
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Addex Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.1 M9.6 M17 M
Slightly volatile
Short and Long Term Debt Total35.9 K37.8 K409.5 K
Slightly volatile
Other Current Liabilities443.6 K467 K1.2 M
Slightly volatile
Total Current Liabilities685.8 K721.9 K2.9 M
Slightly volatile
Total Stockholder Equity8.3 M8.7 M13.5 M
Slightly volatile
Property Plant And Equipment Net36.5 K38.4 K741.6 K
Slightly volatile
Current Deferred Revenue412.9 K270.2 K286.7 K
Slightly volatile
Accounts Payable216.6 K228 K1.3 M
Slightly volatile
Cash2.9 M3 M13.9 M
Slightly volatile
Non Current Assets Total6.7 M6.4 M2.4 M
Pretty Stable
Non Currrent Assets Other6.1 K6.4 K496.9 K
Slightly volatile
Cash And Short Term Investments2.9 M3 M13.9 M
Slightly volatile
Common Stock Total Equity39.7 M37.8 M22.3 M
Slightly volatile
Common Stock Shares Outstanding987.3 K940.2 K328.7 K
Slightly volatile
Liabilities And Stockholders Equity9.1 M9.6 M17 M
Slightly volatile
Other Current Assets151.9 K159.9 K474.1 K
Slightly volatile
Other Stockholder Equity289.3 M379.7 M276.7 M
Slightly volatile
Total Liabilities855.9 K900.9 K3.5 M
Slightly volatile
Property Plant And Equipment Gross167.9 K176.8 K1.5 M
Very volatile
Total Current Assets3 M3.2 M14.6 M
Slightly volatile
Short Term Debt8 K8.4 K107.5 K
Slightly volatile
Common Stock2 M2.1 M13.4 M
Very volatile
Non Current Liabilities Total217.3 K228.8 K614 K
Very volatile
Net Receivables13.3 K14 K357.8 K
Slightly volatile
Other Assets66 K48.9 K141.1 K
Slightly volatile
Capital Surpluse297.8 M329.3 M278.2 M
Slightly volatile
Property Plant Equipment275.1 K458.5 K233 K
Slightly volatile
Net Invested Capital11.3 M8.7 M8.4 M
Slightly volatile
Net Working Capital2.3 M2.5 M7.4 M
Pretty Stable
Capital Stock1.6 M1.7 M22.4 M
Slightly volatile

Addex Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization222.4 K234.1 K635.5 K
Slightly volatile
Total Revenue345.5 K363.7 K1.6 M
Pretty Stable
Other Operating Expenses2.7 M2.8 M11.5 M
Slightly volatile
Research Development372.1 K391.7 K4 M
Pretty Stable
Total Operating Expenses2.7 M2.8 M9.8 M
Slightly volatile
Selling General Administrative1.4 M1.5 M4.5 M
Slightly volatile
Interest Income7.8 K8.2 K87.4 K
Slightly volatile
Reconciled Depreciation270.5 K299.1 K155.5 K
Slightly volatile
Selling And Marketing Expenses1.8 M2 M2.2 M
Slightly volatile

Addex Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.2 M2.1 M1.2 M
Slightly volatile
Begin Period Cash Flow3.3 M3.5 M16.4 M
Slightly volatile
Depreciation222.4 K234.1 K635.5 K
Slightly volatile
End Period Cash Flow2.9 M3 M13.9 M
Slightly volatile
Issuance Of Capital Stock206 K216.8 K22.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.9515.74206
Slightly volatile
PTB Ratio0.50.5210.9448
Pretty Stable
Days Sales Outstanding15.0915.88771
Slightly volatile
Book Value Per Share0.110.09861.1778
Slightly volatile
Average Payables1.4 M1.4 M1.2 M
Slightly volatile
Stock Based Compensation To Revenue2.962.982.7974
Very volatile
Capex To Depreciation0.00530.00560.3301
Pretty Stable
PB Ratio0.50.5210.9448
Pretty Stable
Payables Turnover3.363.044.8137
Pretty Stable
Sales General And Administrative To Revenue6.166.4821.2921
Slightly volatile
Average Inventory62.3 K73.3 K75.3 K
Very volatile
Research And Ddevelopement To Revenue1.581.6711.9693
Slightly volatile
Capex To Revenue0.00340.00360.325
Slightly volatile
Cash Per Share0.03720.03921.2138
Slightly volatile
Days Payables Outstanding1181241.9 K
Pretty Stable
Intangibles To Total Assets0.00230.0030.0034
Pretty Stable
Net Debt To EBITDA0.780.822.5315
Very volatile
Current Ratio6.335.074.8036
Very volatile
Tangible Book Value Per Share0.110.09861.1754
Slightly volatile
Receivables Turnover24.9823.7912.3343
Slightly volatile
Graham Number0.320.360.3924
Slightly volatile
Shareholders Equity Per Share0.110.09861.1778
Slightly volatile
Debt To Equity0.00370.00390.0384
Pretty Stable
Capex Per Share0.00.00.0088
Slightly volatile
Graham Net Net0.02620.02760.9672
Slightly volatile
Average Receivables91.1 K95.9 K287.4 K
Slightly volatile
Revenue Per Share0.00460.00480.1208
Slightly volatile
Interest Debt Per Share5.0E-45.0E-40.0115
Slightly volatile
Debt To Assets0.00340.00350.0195
Pretty Stable
Price Book Value Ratio0.50.5210.9448
Pretty Stable
Days Of Payables Outstanding1181241.9 K
Pretty Stable
Ebt Per Ebit1.681.61.145
Slightly volatile
Company Equity Multiplier1.50.991.9705
Very volatile
Total Debt To Capitalization0.00370.00390.0336
Pretty Stable
Debt Equity Ratio0.00370.00390.0384
Pretty Stable
Quick Ratio6.335.074.8011
Very volatile
Cash Ratio6.054.794.555
Very volatile
Days Of Sales Outstanding15.0915.88771
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.151.0206
Slightly volatile
Price To Book Ratio0.50.5210.9448
Pretty Stable
Fixed Asset Turnover8.218.6454.1482
Very volatile
Debt Ratio0.00340.00350.0195
Pretty Stable
Price Sales Ratio14.9515.74206
Slightly volatile
Asset Turnover0.03290.03460.0916
Slightly volatile
Price Fair Value0.50.5210.9448
Pretty Stable

Addex Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.1 M6.5 M39.2 M
Slightly volatile

Addex Fundamental Market Drivers

Addex Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Addex Therapeutics Financial Statements

Addex Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Addex Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue270.2 K412.9 K
Total Revenue363.7 K345.5 K
Cost Of Revenue768.9 K730.4 K
Stock Based Compensation To Revenue 2.98  2.96 
Sales General And Administrative To Revenue 6.48  6.16 
Research And Ddevelopement To Revenue 1.67  1.58 
Ebit Per Revenue(6.05)(6.35)

Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Addex Stock

  0.7DSGN Design TherapeuticsPairCorr
  0.49ENGN enGene Holdings CommonPairCorr
  0.47IMMP Immutep Ltd ADRPairCorr
  0.42KYTX Kyverna TherapeuticsPairCorr
  0.39ALT AltimmunePairCorr
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:
How To Invest In Addex
Details
Is Addex Stock a good investment?
Details
What is Addex Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Biotechnology sector continue expanding? Could Addex diversify its offerings? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Addex Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(9.24)
Revenue Per Share
0.24
Quarterly Revenue Growth
(0.15)
Return On Assets
(0.16)
Return On Equity
(0.73)
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Understanding that Addex Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Addex Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Addex Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY